Mira Pharmaceuticals (MIRA) Short term Debt (2022 - 2023)

Mira Pharmaceuticals (MIRA) posted Short term Debt of $1.8 million for Q2 2023, up 1254.99% sequentially from $133062.0 in Q4 2022.

Mira Pharmaceuticals (MIRA) Short term Debt (2022 - 2023) Analysis & Trends

Mira Pharmaceuticals (MIRA) has 2 years of Short term Debt data on file, last reported at $1.8 million in Q2 2023.

  • Quarterly Short term Debt changed N/A year-over-year to $1.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.8 million (changed N/A YoY) and the FY2022 annual result came in at $133062.0, changed N/A from the prior year.
  • Short term Debt climbed to $1.8 million in Q2 2023 per MIRA's latest filing, from $133062.0 in the prior quarter.
  • The five-year high for Short term Debt was $1.8 million in Q2 2023, with the low at $133062.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Mira Pharmaceuticals 22.51 Mn 11.48 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2023 1.80 Mn
Dec 31, 2022 133,062.00